Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid Shot

Ireland News News

Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid Shot
Ireland Latest News,Ireland Headlines
  • 📰 Forbes
  • ⏱ Reading Time:
  • 28 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 53%

Pfizer and BioNTech have begun a clinical trial for their omicron-specific coronavirus vaccine

, the companies announced Tuesday, as vaccine makers scramble to reformulate shots to target the infectious variant. The study will evaluate the vaccine for safety, tolerability and strength of immune response in up to 1,420 healthy adults ages 18 to 55, the companies said in a statement.

The companies will test the vaccine in unvaccinated people as part of a three-shot course, as a booster shot in those who have received two Pfizer-BioNTech doses already and as a fourth dose for people who have already had three Pfizer-BioNTech shots. The trial will compare between a fourth dose of the omicron-specific vaccine and a fourth dose of the original vaccine.

The companies said they do not expect manufacturing capacity—an estimated four billion doses in 2022—to change if they pivot to an omicron-specific shot.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Forbes /  🏆 394. in US

Ireland Latest News, Ireland Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotClinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »

Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotClinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »

Pfizer and BioNTech begin clinical trial for Omicron-specific vaccinePfizer and BioNTech begin clinical trial for Omicron-specific vaccinePfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.
Read more »

Pfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer and BioNTech said Tuesday they've stated clinical trials for an omicron-based COVID-19 vaccine.
Read more »

Pfizer Begins Clinical Trial For Omicron-Targeting VaccinePfizer Begins Clinical Trial For Omicron-Targeting VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant.
Read more »

Pfizer starts clinical trial for omicron-specific Covid vaccinePfizer starts clinical trial for omicron-specific Covid vaccineJUST IN: Pfizer and BioNTech announce that they have started a clinical trial testing a modified Covid-19 vaccine to protect against the omicron variant.
Read more »



Render Time: 2025-03-13 18:10:43